Evidence map›Paper›PMID 27444967›Full record

ArticleBrain, behavior, and immunity2016

Neuronal Pentraxin 2 predicts medial temporal atrophy and memory decline across the Alzheimer's disease spectrum.

Ashley Swanson, A A Willette, Alzheimer’s Disease Neuroimaging Initiative

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain, behavior, and immunity, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer's disease pathophysiology.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Trial
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Associations between fluid biomarkers and PET imaging ([11C]UCB-J) of synaptic pathology in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  17. Development and validation of a novel Simoa assay for NPTX2 in Alzheimer's disease and Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  18. Article
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ashley SwansonDepartment of Food Science and Human Nutrition, Iowa State University, Ames, IA, United States.
A A WilletteDepartment of Food Science and Human Nutrition, Iowa State University, Ames, IA, United States; Department of Psychology, Iowa State University, Ames, IA, United States; Aging Mind and Brain Institute, University of Iowa, Iowa City, IA, United States. Electronic address: awillett@iastate.edu.
Alzheimer’s Disease Neuroimaging Initiative

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Insulin Resistance, Biomarkers of Brain Function, and Intermittent Calorie RestrictionR00AG047282 · NIA · IOWA STATE UNIVERSITY · PI WILLETTE, AURIEL · 2016 to 2021
$730k
Insulin Resistance, Biomarkers of Brain Function, and Intermittent Calorie RestrictionK99AG047282 · NIA · IOWA STATE UNIVERSITY · PI WILLETTE, AURIEL · 2015 to 2015
$135k
NIA NIH HHS K99 AG047282NIA NIH HHS R00 AG047282NIA NIH HHS U01 AG024904
6 · The paper itself

Abstract

Chronic neuroinflammation is thought to potentiate medial temporal lobe (MTL) atrophy and memory decline in Alzheimer's disease (AD). It has become increasingly important to find novel immunological biomarkers of neuroinflammation or other processes that can track AD development and progression. Our study explored which pro- or anti-inflammatory cerebrospinal fluid (CSF) biomarkers best predicted AD neuropathology over 24months. Using Alzheimer's Disease Neuroimaging Initiative data (N=285), CSF inflammatory biomarkers from mass spectrometry and multiplex panels were screened using stepwise regression, followed up with 50%/50% model retests for validation. Neuronal Pentraxin 2 (NPTX2) and Chitinase-3-like-protein-1 (C3LP1), biomarkers of glutamatergic synaptic plasticity and microglial activation respectively, were the only consistently significant biomarkers selected. Once these biomarkers were selected, linear mixed models were used to analyze their baseline and longitudinal associations with bilateral MTL volume, memory decline, global cognition, and established AD biomarkers including CSF amyloid and tau. Higher baseline NPTX2 levels corresponded to less MTL atrophy [R

Indexed as

AgedAlzheimer DiseaseAmyloid beta-PeptidesAtrophyBiomarkersChitinase-3-Like Protein 1C-Reactive ProteinEncephalitisFemaleHumansMaleNerve Tissue ProteinsNeuropsychological TestsPentraxinstau ProteinsTemporal LobeAmyloid beta-PeptidesBiomarkersChitinase-3-Like Protein 1C-Reactive ProteinMAPT protein, humanNerve Tissue ProteinsPentraxinstau ProteinsAlzheimer’s diseaseAmyloidBiomarkersC3LP1ImmunologyInflammationMedial temporal lobeMemoryNPTX2Tau

Identifiers

PMID27444967
PMCPMC5349324

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.